REHACELL is a leading clinical stage biopharmaceutical stem cell company based in Heidelberg, Germany. We focus on innovative stem cell therapies for patients suffering from severe inflammation-driven diseases with high unmet medical need. Founded in 2012, RHEACELL’s declared goal is to help patients, that would have no other therapy options. We fight rare diseases!

Our innovative proprietary cell therapy with ABCB5+ mesenchymal stem cells as pure drug substance (platform technology) targets inflammation, enabling recovery of normal physiological function. Unique product characteristics and mode of action: first systematic treatment targeting external and internal wounds. Reduction of overall disease burden in patients. Immune modulatory mode of action and anti-inflammatory affect leads to curative treatment components.

Based on the mode of action and relevant potency assays, RHEACELL has a broad pipeline to further broaden its clinical development and market access into different rare and orphan diseases.